证券日报网讯1月8日，友阿股份（002277）在互动平台回答投资者提问时表示，公司第四季度业绩波动 与零售行业季节性及年末审慎会计处理的普遍特征相符。具体到2024年度，第四季度归母净利润环比降 幅较大，主要系根据会计政策在年末集中计提了坏账准备、存货跌价准备等各项资产减值准备，以及根 据相关诉讼终审判决结果计提了相应利息所致。2025年具体财务数据请以公司后续正式披露的年度报告 为准。 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 石家庄通合电子科技股份有限公司（以下简称"通合科技"）近日发布《关于申请向不特定对象发行可转 换公司债券审核问询函的回复报告》，就深圳证券交易所提出的业绩波动、毛利率变化、现金流状况等 七大方面问题进行了详细说明。公司同时披露了2025年1-9月财务数据，期内实现营业收入9.75亿元， 同比增长32.40%；归母净利润2043.78万元，同比下降2.20%，业绩降幅较2024年的-76.66%已明显收 窄。 业绩波动原因：新能源业务价格竞争与成本压力交织 公告显示，通合科技2023年营业收入和利润大幅增长，2024年至今收入持续增长但净利润下滑，主要受 新能源功率变换业务影响。该业务收入占比超过60%，2023年因高功率产品占比提升（从22.11%增至 54.17%）带动毛利率同比提高9.9个百分点至28.27%；2024年以来，受行业竞争加剧影响，产品平均售 价下降9.92%，尽管单位成本降低2.52%，但降价幅度大于降本幅度，导致毛利率回落至22.38%。 分业务板块来看，2025年1-9月： -新能源功率变换业务：收入6.45亿元（+25.34%），毛利 ...

记者丨李益文 编辑丨叶映橙 12月1日，21财经《辟谣财知道》注意到，市场出现有关印制电路板龙头企业胜宏科技（300476.SZ）第四季度业绩有变的相关 传闻，引发投资者关注。 对此，21财经·南财快讯记者以投资者身份致电胜宏科技，接线工作人员表示，目前市场流传的相关业绩预告并非公司发布，且 公司在手订单正常，未出现异常情况。此前影响第三季度业绩的"料号切换"问题已结束，但公司暂未披露第四季度的业绩预 测。 截至12月1日收盘，胜宏科技股价报268.82元/股，微跌0.69%，年内涨幅仍高达541.27%。 出品丨21财经客户端 21世纪经济报道 编辑丨黎雨桐 实习生丁紫祎 （声明：文章内容仅供参考，不构成投资建议。投资者据此操作，风险自担。） 尽管同比数据亮眼，但第三季度归母净利润较第二季度的12.23亿元环比下降9.88%。受此影响，10月28日，胜宏科技股价盘中 一度跌超7%，而自三季报披露至今，其股价开启震荡走低态势，目前已累计下滑21%。 针对净利环比下滑，胜宏科技在电话会上解释称，主要受三大因素影响： 一是配合客户需求进行HDI产线调整导致短期产能波动；二是新厂房投产后员工数量增加约两三千人，人力 ...

Core Viewpoint - Dongsheng Jin Cai Technology (Group) Co., Ltd. has announced the termination of its public offering of shares and the withdrawal of its listing application on the Beijing Stock Exchange due to ongoing inquiries and performance updates [1][2] Group 1: IPO and Regulatory Concerns - The company's IPO was accepted on December 30, 2024, but faced multiple delays and inquiries, with the latest round of inquiries still unanswered as of the announcement date [1] - Regulatory scrutiny has focused on the company's declining performance and the rationale behind its fundraising projects [2][7] - The bankruptcy restructuring of the company's largest supplier raised concerns about the stability of raw material supply [2][3] Group 2: Financial Performance - Dongsheng Jin Cai's main business involves the research, production, and sales of aluminum alloy element additives, with approximately 90% of revenue derived from this segment [3] - The company experienced significant revenue fluctuations, with reported revenues of 930 million yuan in 2021, 1.045 billion yuan in 2022, and a drop to 658 million yuan in 2023, marking a 37.05% year-on-year decline [4][9] - The net profit attributable to the parent company also saw a decline from 88.34 million yuan in 2021 to 41.39 million yuan in 2023, a decrease of 66.16% [4][9] Group 3: Supply Chain and Raw Material Dependency - The company has been heavily reliant on its largest supplier, Tianyuan Manganese Industry, which accounted for over 46% of its raw material purchases until its bankruptcy restructuring in September 2023 [3][4] - Despite the bankruptcy, the company claims it has alternative suppliers capable of meeting its raw material needs, thus mitigating supply risks [4][9] Group 4: Sales Model and Market Conditions - The company employs a long-term sales model, which has been criticized for potentially amplifying revenue volatility [7][8] - The decline in 2023 performance was attributed to a combination of factors, including a decrease in sales volume and rising costs, as well as a shift in customer behavior towards inventory reduction [9][10] Group 5: Future Outlook and Expansion Plans - Dongsheng Jin Cai plans to raise 350 million yuan for expansion projects, including the production of 60,000 tons of alloy additives and 30,000 tons of aluminum intermediate alloys [11][12] - The company aims to enhance its research capabilities with a new R&D center, although concerns remain regarding the feasibility of its expansion given current production capacity and market conditions [11][15] - The company anticipates a recovery in demand and profitability in 2024, with projected revenues of 745 million yuan and a net profit of 51 million yuan [9][10]

无锡金杨新材料股份有限公司（简称"金杨股份"）近日发布《审核问询函回复报告》，就深圳证券交易 所关于公司向不特定对象发行可转换公司债券的问询事项进行了详细说明。报告显示，公司2022年至 2025年1-9月营业收入波动增长，但扣非归母净利润持续下滑，电池精密结构件毛利率呈下降趋势。公 司对此解释称，主要受消费电池行业景气度波动、产品价格下降及原材料价格波动等因素影响。 收入与利润变动趋势不一致 毛利率持续下滑 报告期内，金杨股份营业收入分别为12.29亿元、11.10亿元、13.65亿元及11.95亿元，呈现波动增长态 势；扣非归母净利润则从2022年的8789.07万元持续下滑至2025年1-9月的2689.61万元，期间费用增加及 股份支付费用计提是重要原因。2025年1-9月，公司管理费用同比增加74.20%，主要系管理人员薪酬增 加及计提股份支付费用1691.18万元所致。 电池精密结构件毛利率从2022年的21.89%降至2024年的9.80%，2025年1-9月略有回升至11.00%。公司 表示，毛利率下滑主要受产品销售价格下降、方形壳体等新产品市场开拓初期毛利率较低以及原材料价 格波动影响。分产 ...

Core Viewpoint - The stock of HeFu China (603122) experienced significant volatility, with a cumulative increase of 256.29% over a period of 14 trading days, leading to a temporary suspension of trading for verification due to abnormal price fluctuations [1][2] Group 1: Stock Performance and Trading Suspension - HeFu China announced the completion of a trading suspension verification, with the stock set to resume trading on November 20, 2025 [1] - The stock hit the daily limit up on 12 out of 14 trading days, with five instances of abnormal fluctuations and three instances of severe fluctuations [1] - The company’s stock price is currently significantly higher than its operational performance and industry conditions, indicating a potential disconnect [1][2] Group 2: Financial Performance and Valuation - As of November 14, 2025, HeFu China's static price-to-earnings (P/E) ratio was 343.67, compared to the industry average of 30.94, suggesting a bubble in the stock price [2] - The company reported a net loss of 5.048 million yuan in Q3 2025, a year-on-year decline of 225.26%, attributed to changes in the macroeconomic environment and price reductions in the medical industry [2] - Despite implementing cost control measures, the company faces pressure on its short-term operating performance due to declining sales revenue and profit levels [2]

明日复牌。 合富中国（603122）11月19日晚间公告，近期，公司就股票交易异常波动及严重异常波动的相关事项进行了核查。鉴于相关核查 工作已完成，经公司向上海证券交易所申请，公司股票将于11月20日开市起复牌。经公司自查，公司目前日常经营活动一切正 常，公司内外部经营环境未发生重大变化。截至公告披露日，除了在指定媒体上已公开披露的信息外，不存在影响公司股票交易 价格异常波动的重大事宜；不存在其他涉及本公司应披露而未披露的重大信息；未发现可能或已经对公司股票交易价格产生影响 的媒体报道或市场传闻，亦未涉及热点概念事项。 | 证券代码 | 证券简称 | 停复牌类型 | 停牌起 | 停牌 | 停牌终止日 | 复牌日 | | --- | --- | --- | --- | --- | --- | --- | | | | | 始日 | 期间 | | | | 603122 | 合富中国 | A 股 复牌 | | | 2025/11/19 | 2025/11/20 | 公告显示，自2025年10月28日至2025年11月14日期间，公司股票连续14个交易日中有12个交易日以涨停价收盘，并5次触及股价 异常波动、3次触及严 ...

Core Viewpoint - The company, HeFu China (603122), will resume trading on November 20, 2025, after completing an investigation into abnormal stock price fluctuations, confirming that its business operations remain normal and no significant changes have occurred in its internal or external environment [1][2]. Group 1: Stock Trading and Market Performance - The company's stock experienced a significant increase, with a cumulative rise of 256.29% over 14 trading days, during which it hit the daily limit up on 12 occasions and faced severe abnormal fluctuations three times [2]. - The stock's recent performance is characterized by market sentiment that may be overly optimistic, indicating a risk of irrational speculation and potential for a rapid decline [2]. Group 2: Financial Performance and Business Operations - The company reported a net loss of 5.048 million yuan for Q3 2025, primarily due to changes in the domestic macroeconomic environment and price reductions in the medical industry, leading to decreased sales revenue and profit levels [4]. - The company's revenue for the current reporting period decreased by 21.27% year-on-year, while the total profit fell by 193.80% [5]. - The static price-to-earnings (P/E) ratio of the company is significantly higher than that of its industry peers, standing at 343.67 times compared to the industry average of 30.94 times, indicating a potential overvaluation risk [5].

Core Viewpoint - The company, HeFu China, announced that its stock will resume trading on November 20, 2025, after a significant price increase during the trading suspension period [1] Summary by Relevant Sections Stock Performance - From October 28 to November 14, the company's stock experienced a remarkable performance, with 12 out of 14 trading days closing at the daily limit price, resulting in a total increase of 256.29%, significantly outperforming the industry and the Shanghai Composite Index [1] Financial Status - The company's main business remains unchanged; however, it is currently operating at a loss, with a net profit attributable to shareholders of -5.048 million yuan in the third quarter of 2025 [1] - The latest price-to-earnings (P/E) ratio stands at 343.67, which is considerably higher than that of peer companies in the industry [1] Investor Advisory - The company has advised investors to be aware of performance volatility and the risks associated with high valuation, urging rational investment and caution regarding trading risks [1]

Core Viewpoint - Jiangsu Sopo (600746.SH) has experienced significant fluctuations in revenue and net profit from 2022 to the first half of 2025, primarily due to market performance of its core products, acetic acid and ethyl acetate, which have seen declining prices impacting overall gross margins [1][2]. Financial Performance Summary - Revenue figures for Jiangsu Sopo from 2022 to the first half of 2025 are as follows: 7.172 billion, 5.390 billion, 6.403 billion, and 3.158 billion [1]. - Net profit for the same period shows a decline to 0.18 billion in 2023, with a recovery to 2.13 billion in 2024, and 1.02 billion in the first half of 2025 [2]. - The gross margin for the main business has decreased over the years, with figures of 15.58%, 7.62%, 8.72%, and 8.40% respectively [1]. Product Performance Analysis - The decline in gross margin is attributed to the market performance of acetic acid and ethyl acetate, with acetic acid's gross margin dropping from 24.69% and ethyl acetate's margin showing a slight recovery in 2025 due to raw material price decreases [1][2]. - In 2024, net profit recovery was supported by stable operations and increased sales volumes of acetic acid and ethyl acetate, which grew by 36.82% and 20.33% respectively [2]. Industry Comparison - Compared to peers, Jiangsu Sopo's gross margin and net profit trends differ due to its concentrated business model focused on acetic acid and derivatives, while competitors like Hualu Hengsheng have a more diverse product range and lower raw material costs [3]. - The overall industry trend shows a decline in gross margins in 2023 followed by a recovery in 2024, aligning with Jiangsu Sopo's performance despite differences in product composition and cost control capabilities [3].